SYSTEMATIC REVIEW
Accepted on 18 Aug 2025
Evaluation of the Efficacy and Treatment-emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-ranging Meta-analysis of 1372 Randomized Patients
doi 10.3389/fmed.2025.1641245